Unsurprisingly then, when BCL3 was shown in 2019 to enhance β-catenin signaling in a panel of CRC cell lines, that suppression of BCL3 was found to reduce cancer stem cell activity within the tumour populations, as demonstrated by tumoursphere assay and stem cell markers Lgr-5 and Bmi expression [13]. The gene discussed is BCL3; the disease is neoplasm.